VM100 nutritional supplement for quality of life in Duchenne muscular dystrophy
Tests the supplement VM100 against placebo in people with Duchenne muscular dystrophy.
Plain-language title generated from the registry record
Registry title: Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Key facts
- Where
- Gainesville, United StatesSee the site
- Phase
- Phase 2
Where in United States
- University of FloridaGainesville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Florida
- Trial code
- NCT07766980
- Record updated
- 8 October 2026
- Original description
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).Read full original descriptionShow less
Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).
Inclusion: Diagnosis of DMD confirmed by genetic report; Age 8 years or older; Stable glucocorticoid and/or other medication regimen for at least 3 months before enrollment and throughout study participation.
Exclusion: Unstable medical conditions or significant concomitant illness; Participation in another investigational clinical trial within the previous 3 months; Secondary condition affecting muscle function or metabolism (e.g., myasthenia gravis, endocrine disorders, mitochondrial disease).